


(I)

wherein

B is cytosine or 5-fluorocytosine,

R is H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, or



*C2
Cmt*
Rc is in each case independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or a hydroxy protecting group, and wherein said compound is substantially in the form of the (-) enantiomer; and

a chemotherapeutic agent selected from Asparaginase, Bleomycin, Busulfan, Carmustine, Chlorambucil, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin, Doxorubicin, Etoposide, Fludarabine, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Lomustine, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Pentostatin, Procarbazine, 6-Thioguanine, Topotecan, Vinblastine, Vincristine, Dexamethasone, Retinoic acid and Prednisone.--

Please add the following new claims:

3
--60. A method according to claim 11, wherein said compound of formula I is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.

61. A method according to claim 22, wherein said compound of formula I is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.

62. A composition according to claim 38, wherein said compound of formula I is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.

63. A combination according to claim 57, wherein said compound of formula I is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof, and said chemotherapeutic agent is Doxorubicin.--

(N3)
Cont